Recordati Stock Quote REC - Stock Price, News, Charts, Message Board, Trades

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

50.95

Bid

50.90

Ask

51.00

Volume

57,974

50.60 Day's Range 51.00

46.49 52 Week Range 54.80

Market Cap

10.463B

Previous Close

51.05

Open

50.85

Last Trade

50.95

Last Trade Time

07:03:16

Financial Volume

VWAP

Average Volume (3m)

272,707

Shares Outstanding

205,358,104

Dividend Yield

2.41%

PE Ratio

27.57

Earnings Per Share (EPS)

1.9

Revenue

2.07B

Net Profit

389.21M

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.recordati.it

Headquarters

Milan, Lombardy, Ita

Founded

1926

Recordati SpA is listed in the Pharmaceutical Preparations sector of the Italian Stock Exchange with ticker REC. The last closing price for Recordati was 51.05 €. Over the last year, Recordati shares have traded in a share price range of 46.49 € to 54.80 €.

Recordati currently has 205,358,104 shares outstanding. The market capitalization of Recordati is 10.48 € billion. Recordati has a price to earnings ratio (PE ratio) of 27.57.

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5% Consolidated net revenue of € 1,743.1 million in the...

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE Milan, 4th October 2024 – Recordati today announces an agreement with Sanofi...

Recordati Rare Diseases annonce la publication dans The Journal of Clinical Endocrinology & Metabolism des résultats de l’étude de Phase III LINC 4 confirmant l'efficacité et la tolérance d’Isturisa® (osilodrostat)...

L’étude LINC 4 a démontré la supériorité d’Isturisa® (osilodrostat) comparé au placebo pour normaliser le cortisol au cours de la phase de 12 semaines en double aveugle, randomisée de l’étude (77...

RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICON...

RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICONFERMANO L’EFFICACIA E LA SICUREZZA DI ISTURISA® (OSILODROSTAT) PER...

Recordati Rare Diseases: Positive Results From the Phase III LINC 4 Study Presented Today at the Endocrine Society’s Annual...

Statistically significant results from the pivotal Phase III LINC 4 study demonstrate that Isturisa® (osilodrostat) provides rapid and sustained normalisation of mean urinary free cortisol levels...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.8	-1.54589371981	51.75	52.2	50.6	286500	51.54522272	DE
4	0	0	50.95	54.1	49.48	284032	51.34179204	DE
12	-0.05	-0.0980392156863	51	54.8	48.58	272707	51.81441748	DE
26	1.41	2.84618490109	49.54	54.8	47.38	245593	51.04476484	DE
52	4.16	8.89078863005	46.79	54.8	46.49	238313	50.59125486	DE
156	-2.47	-4.6237364283	53.42	56.96	34.52	234897	45.67704867	DE
260	14.95	41.5277777778	36	57.9	28.26	281136	44.90825561	DE

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
WS3D25Solid World Group spa	0.2399 € (27.61%)	50.38k
EEMSEEMS Italia SPA	0.2057 € (21.14%)	776.6k
1WBAWalgreens Boots Alliance Inc	9.80 € (16.64%)	2.35k
S3DSolid World Group spa	2.32 € (12.35%)	184.8k
SBCSicily by Car SpA	3.67 € (11.89%)	7.48k
WRKT25Roket Sharing Company Spa	0.0025 € (-21.88%)	15k
1DHERDelivery Hero SE	31.71 € (-18.06%)	13
NPINotorious Pictures S.p.A.	0.72 € (-10.00%)	1.2k
WLDB24Lindbergh Spa	0.4372 € (-9.86%)	136.98k
1AFXCarl Zeiss Meditec AG	56.10 € (-7.96%)	305
TITTelecom Italia SpA	0.2486 € (2.35%)	116.77M
SPMSaipem Spa	2.563 € (3.06%)	36.26M
ISPIntesa Sanpaolo Spa	3.834 € (0.38%)	20.46M
TITRTelecom Italia	0.2877 € (2.79%)	19.34M
RNRisanamento	0.03 € (2.04%)	9.94M